Narcolepsy

Sleep Medicine Clinics

Volumn 1, Issue 1, 2006, Pages 47-61

  Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 64749104762     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2005.11.008     Document Type: Review

References (85)

1. Hublin C., Kaprio J., Partinene M., et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 35 (1994) 709-716
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 (1998) S16-S22
3. American Academy of Sleep Medicine. ICSD-2-International classification of sleep disorders. Diagnostic and coding manual. 2nd edition (2005), American Academy of Sleep Medicine, Westchester (IL)
4. Beusterien K.M., Rogers A.E., Walsleben J.A., et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22 (1999) 757-765
5. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
6. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9 (2005) 269-310
7. Nishino S., and Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52 (1997) 27-78
8. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y., and Juji T. (Eds). HLA in narcolepsy (1988), Springer-Verlag, New York 24-57
9. Gelb M., Guilleminault C., Kraemer H., et al. Stability of cataplexy over several months-information for the design of therapeutic trials. Sleep 17 (1994) 265-273
10. Overeem S., Mignot E., van Dijk J.G., et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18 (2001) 78-105
11. Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25 (2002) 42-49
12. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
13. Nishino S., Kanbayashi T., Fujiki N., et al. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 61 (2003) 823-825
14. Overeem S., Dalmau J., Bataller L., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 (2004) 138-140
15. Alaila S.L. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M., Pollak C.P., Cohen F.L., et al. (Eds). Loss, grief and care: psychosocial aspects of narcolepsy, vol. 5 (1992), Haworth Press, New York 1-22
16. Black J.E., Brooks S.N., and Nishino S. Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 24 (2004) 271-282
17. Smolik P., and Roth B. Kleine-Levin syndrome ethiopathogenesis and treatment. Acta Univ Carol Med Monogr 128 (1988) 5-94
18. Billiard M. Kleine Levin syndrome. In: Krieger M.H., Roth T., and Dement W.C. (Eds). Principles and practice of sleep medicine (1989), WB Saunders, Philadelphia 377-378
19. Dement W., Rechtschaffen A., and Gulevich G. The nature of the narcoleptic sleep attack. Neurology 16 (1966) 18-33
20. Broughton R., Valley V., Aguirre M., et al. Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 9 (1986) 205-215
21. Guilleminault C., Wilson R.A., and Dement W.C. A study on cataplexy. Arch Neurol 31 (1974) 255-261
22. Nishino S., Riehl J., Hong J., et al. Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 38 (2000) 437-446
23. Bishop C., Rosenthal L., Helmus T., et al. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 19 (1996) 727-730
24. Aldrich M.S., Chervin R.D., and Malow B.A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 20 (1997) 620-629
25. Fukuda K., Miyasita A., Inugami M., et al. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 10 (1987) 279-286
26. Ohayon M.M., Priest R.G., Caulet M., et al. Hypnagogic and hypnopompic hallucinations: pathological phenomena?. Br J Psychiatry 169 (1996) 459-467
27. Juji T., Satake M., Honda Y., et al. HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive. Tissue Antigens 24 (1984) 316-319
28. Mignot E., Hayduk R., Black J., et al. HLA class II studies in 509 narcoleptic patients. Sleep Res 26 (1997) 433
29. Mignot E., Guilleminault C., Grumet F.C., et al. Is narcolepsy an autoimmune disease?. In: Smirne S., Francesci M., Ferini-Strambi L., et al. (Eds). Proceedings of the Third Milano International Symposium, September 18-19 Sleep, Hormones, and the Immune System (1992), Masson, Milan 29-38
30. Billiard M., Laaberki M.F., Reygrobellet C., et al. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 18 (1989) 201
31. Montplaisir J., Poirier G., Lapierre O., et al. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia. Sleep Res 18 (1989) 271
32. Frederickson S., Carlander B., Billiard M., et al. CSF immune variable in patients with narcolepsy. Acta Neurol Scand 81 (1990) 253-254
33. Matsuki K., Juji T., and Honda Y. Immunological features of narcolepsy in Japan. In: Honda Y., and Juji T. (Eds). HLA in narcolepsy (1988), Springer-Verlag, New York 150-157
34. Black III J.L., Krahn L.E., Pankratz V.S., et al. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 25 (2002) 719-723
35. Black III J.L., Silber M.H., Krahn L.E., et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 58 (2005) 504-509
36. Mignot E., Wang C., Rattazzi C., et al. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci U S A 88 (1991) 3475-3478
37. Chemelli R.M., Willie J.T., Sinton C.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
38. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
39. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
40. Nishino S., Ripley B., Overeem S., et al. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50 (2001) 381-388
41. Krahn L.E., Pankratz V.S., Oliver L., et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25 (2002) 733-736
42. Kanbayashi T., Inoue Y., Chiba S., et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 11 (2002) 91-93
43. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
44. Ripley B., Fujiki N., Okura M., et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 8 (2001) 525-534
45. De Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1998) 322-327
46. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
47. Peyron C., Tighe D.K., van den Pol A.N., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18 (1998) 9996-10015
48. Willie J.T., Chemelli R.M., Sinton C.M., et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 24 (2001) 429-458
49. Taheri S., Zeitzer J.M., and Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 25 (2002) 283-313
50. Nishino S., Fujiki N., Ripley B., et al. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 313 (2001) 125-128
51. Huang Z.L., Qu W.M., Li W.D., et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 98 (2001) 9965-9970
52. Yamanaka A., Tsujino N., Funahashi H., et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 290 (2002) 1237-1245
53. Eriksson K.S., Sergeeva O., Brown R.E., et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 21 (2001) 9273-9279
54. Nishino S., Sakurai E., Nevisimalova S., et al. CSF histamine content is decreased in hypocretin-deficient human narcolepsy. Sleep 25 (2002) A476
55. Shiba T., Fujiki N., Wisor J., et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 27 suppl (2004) A241
56. Fujiki N., Yoshida Y., Ripley B., et al. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 12 (2001) 993-997
57. Yoshida Y., Fujiki N., Nakajima T., et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14 (2001) 1075-1081
58. Zeitzer J.M., Buckmaster C.L., Parker K.J., et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23 (2003) 3555-3560
59. Mileykovskiy B.Y., Kiyashchenko L.I., and Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46 (2005) 787-798
60. Lee M.G., Hassani O.K., and Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 25 (2005) 6716-6720
61. Aston-Jones G., Chen S., Zhu Y., et al. A neural circuit for circadian regulation of arousal. Nat Neurosci 4 (2001) 732-738
62. Wu M.F., John J., Maidment N., et al. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 283 (2002) R1079-R1086
63. Roehrs T., Zorick F., Wittig R., et al. Alerting effects of naps in patients with narcolepsy. Sleep 9 (1986) 194-199
64. Thorpy M.J., and Goswami M. Treatment of narcolepsy. In: Thorpy M.J. (Ed). Handbook of sleep disorders (1990), Marcel Dekker, New York 235-258
65. Mullington J., and Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 16 (1993) 444-456
66. Rogers A.E. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs 16 (1984) 326-334
67. American Narcolepsy Association. Stimulant medication survey. The Eye Opener (1992) 1-3
68. Mitler M.M., Aldrich M.S., Koob G.F., et al. Narcolepsy and its treatment with stimulants. Sleep 17 (1994) 352-371
69. Lammers G.J., Arends J., Declerck A.C., et al. Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16 (1993) 216-220
70. Scrima L., Hartman P.G., Johnson F.H., et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 26 (1989) 331-343
71. Nishino S., Okura M., and Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 4 (2000) 57-99
72. Mignot E. Pathophysiology of narcolepsy. In: Kryger M.H., Roth T., Dement W.C., et al. (Eds). Principles and practice of sleep medicine (2000), WB Saunders, Philadelphia 663-675
73. Nishino S., Mao J., Sampathkumaran R., et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online 1 (1998) 49-61. http://www.sro.org/1998/Nishino/49 Accessed December 24, 2005
74. Wisor J.P., Nishino S., Sora I., et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21 (2001) 1787-1794
75. Babcock D.A., Narver E.L., Dement W.C., et al. Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 5 (1976) 599-602
76. Foutz A.S., Delashaw J.B., Guilleminault C., et al. Monoaminergic mechanisms and experimental cataplexy. Ann Neurol 10 (1981) 369-376
77. Kiyashchenko L.I., Mileykovskiy B.Y., Lai Y.Y., et al. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J Neurophysiol 85 (2001) 2008-2016
78. Nambu T., Sakurai T., Mizukami K., et al. Distribution of orexin neurons in the adult rat brain. Brain Res 827 (1999) 243-260
79. Hagan J.J., Leslie R.A., Patel S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 96 (1999) 10911-10916
80. Horvath T.L., Peyron C., Diano S., et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 415 (1999) 145-159
81. Fujiki N., Ripley B., Yoshida Y., et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 6 (2003) 953-959
82. Kanbayashi T., Yano T., Ishiguro H., et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep 25 (2002) 337-339
83. Kubota H., Kanbayashi T., Tanabe Y., et al. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 17 (2002) 537-539
84. Hara J., Beuckmann C.T., Nambu T., et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30 (2001) 345-354
85. Nishino S. The hypocretin/orexin system in health and disease. Biol Psychiatry 54 (2003) 87-95